dwn12088

dwn12088: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Lead developer: CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH)

Get the AI investment thesis on dwn12088

Development Pipeline (1)

Clinical Trials (1)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis

NCT05389215·Phase 2·CTTH
Active, not recruiting

Frequently asked questions

Who is developing dwn12088?

dwn12088 is being developed by CTT PHARMACEUTICAL HOLDINGS, INC..

How many clinical trials involve dwn12088?

BioSniper tracks 1 clinical trial involving dwn12088.

Analyze CTT PHARMACEUTICAL HOLDINGS, INC. & dwn12088 with AI

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start AI Analysis